Literature DB >> 19068476

Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests.

Tanguy Fortin1, Arnaud Salvador, Jean Philippe Charrier, Cristof Lenz, Xavier Lacoux, Aymeric Morla, Geneviève Choquet-Kastylevsky, Jérôme Lemoine.   

Abstract

Proteomics discovery leads to a list of potential protein biomarkers that have to be subsequently verified and validated with a statistically viable number of patients. Although the most sensitive, the development of an ELISA test is time-consuming when antibodies are not available and need to be conceived. Mass spectrometry analysis driven in quantitative multiple reaction monitoring mode is now appearing as a promising alternative to quantify proteins in biological fluids. However, all the studies published to date describe limits of quantitation in the low microg/ml range when no immunoenrichment of the target protein is applied, whereas the concentration of known clinical biomarkers is usually in the ng/ml range. Using prostate-specific antigen as a model biomarker, we now provide proof of principle that mass spectrometry enables protein quantitation in a concentration range of clinical interest without immunoenrichment. We have developed and optimized a robust sample processing method combining albumin depletion, trypsin digestion, and solid phase extraction of the proteotypic peptides starting from only 100 microl of serum. For analysis, mass spectrometry was coupled to a conventional liquid chromatography system using a 2-mm-internal diameter reverse phase column. This mass spectrometry-based strategy was applied to the quantitation of prostate-specific antigen in sera of patients with either benign prostate hyperplasia or prostate cancer. The quantitation was performed against an external calibration curve by interpolation, and results showed good correlation with existing ELISA tests applied to the same samples. This strategy might now be implemented in any clinical laboratory or certified company for further evaluation of any putative biomarker in the low ng/ml range of serum or plasma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19068476      PMCID: PMC2689759          DOI: 10.1074/mcp.M800238-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  22 in total

1.  Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS.

Authors:  Scott A Gerber; John Rush; Olaf Stemman; Marc W Kirschner; Steven P Gygi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-27       Impact factor: 11.205

2.  Albumin depletion of human plasma also removes low abundance proteins including the cytokines.

Authors:  Jill Granger; Javed Siddiqui; Shannon Copeland; Daniel Remick
Journal:  Proteomics       Date:  2005-12       Impact factor: 3.984

3.  Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins.

Authors:  Leigh Anderson; Christie L Hunter
Journal:  Mol Cell Proteomics       Date:  2005-12-06       Impact factor: 5.911

4.  Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia.

Authors:  A Zisman; E Zisman; A Lindner; S Velikanov; Y I Siegel; E Mozes
Journal:  J Urol       Date:  1995-09       Impact factor: 7.450

5.  Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin.

Authors:  W M Zhang; P Finne; J Leinonen; S Vesalainen; S Nordling; S Rannikko; U H Stenman
Journal:  Clin Chem       Date:  1998-12       Impact factor: 8.327

Review 6.  Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values.

Authors:  A Semjonow; B Brandt; F Oberpenning; S Roth; L Hertle
Journal:  Prostate Suppl       Date:  1996

7.  Clinical usefulness of free and complexed PSA.

Authors:  A F Prestigiacomo; T A Stamey
Journal:  Scand J Clin Lab Invest Suppl       Date:  1995

8.  Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry.

Authors:  David R Barnidge; Marcia K Goodmanson; George G Klee; David C Muddiman
Journal:  J Proteome Res       Date:  2004 May-Jun       Impact factor: 4.466

9.  Efficient and specific removal of albumin from human serum samples.

Authors:  Laura F Steel; Michael G Trotter; Pamela B Nakajima; Taj S Mattu; Gregory Gonye; Timothy Block
Journal:  Mol Cell Proteomics       Date:  2003-05-16       Impact factor: 5.911

Review 10.  Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era.

Authors:  R T McCormack; H G Rittenhouse; J A Finlay; R L Sokoloff; T J Wang; R L Wolfert; H Lilja; J E Oesterling
Journal:  Urology       Date:  1995-05       Impact factor: 2.649

View more
  45 in total

Review 1.  Biomedical mass spectrometry in today's and tomorrow's clinical microbiology laboratories.

Authors:  Alex van Belkum; Martin Welker; Marcel Erhard; Sonia Chatellier
Journal:  J Clin Microbiol       Date:  2012-02-22       Impact factor: 5.948

Review 2.  Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions.

Authors:  Paola Picotti; Ruedi Aebersold
Journal:  Nat Methods       Date:  2012-05-30       Impact factor: 28.547

Review 3.  Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS.

Authors:  Jessica O Becker; Andrew N Hoofnagle
Journal:  Bioanalysis       Date:  2012-02       Impact factor: 2.681

4.  Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring.

Authors:  Akos Végvári; Karin Sjödin; Melinda Rezeli; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga
Journal:  Mol Cell Proteomics       Date:  2013-07-10       Impact factor: 5.911

Review 5.  Stable-isotope dilution LC–MS for quantitative biomarker analysis.

Authors:  Eugene Ciccimaro; Ian A Blair
Journal:  Bioanalysis       Date:  2010-02       Impact factor: 2.681

6.  Investigation of Ion Transmission Effects on Intact Protein Quantification in a Triple Quadrupole Mass Spectrometer.

Authors:  Evelyn H Wang; Dananjaya Kalu Appulage; Erin A McAllister; Kevin A Schug
Journal:  J Am Soc Mass Spectrom       Date:  2017-05-30       Impact factor: 3.109

7.  Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer.

Authors:  Sebastien Gallien; Elodie Duriez; Catharina Crone; Markus Kellmann; Thomas Moehring; Bruno Domon
Journal:  Mol Cell Proteomics       Date:  2012-09-07       Impact factor: 5.911

8.  Deep-Dive Targeted Quantification for Ultrasensitive Analysis of Proteins in Nondepleted Human Blood Plasma/Serum and Tissues.

Authors:  Song Nie; Tujin Shi; Thomas L Fillmore; Athena A Schepmoes; Heather Brewer; Yuqian Gao; Ehwang Song; Hui Wang; Karin D Rodland; Wei-Jun Qian; Richard D Smith; Tao Liu
Journal:  Anal Chem       Date:  2017-08-11       Impact factor: 6.986

9.  Multiple Reaction Monitoring for Direct Quantitation of Intact Proteins Using a Triple Quadrupole Mass Spectrometer.

Authors:  Evelyn H Wang; Peter C Combe; Kevin A Schug
Journal:  J Am Soc Mass Spectrom       Date:  2016-03-08       Impact factor: 3.109

10.  Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests.

Authors:  Tao Liu; Mahmud Hossain; Athena A Schepmoes; Thomas L Fillmore; Lori J Sokoll; Scott R Kronewitter; Grant Izmirlian; Tujin Shi; Wei-Jun Qian; Robin J Leach; Ian M Thompson; Daniel W Chan; Richard D Smith; Jacob Kagan; Sudhir Srivastava; Karin D Rodland; David G Camp
Journal:  J Proteomics       Date:  2012-02-13       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.